Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review

被引:19
|
作者
Fernandez-Pombo, Antia [1 ,2 ]
Diaz-Lopez, Everardo Josue [1 ,2 ]
Castro, Ana I. [2 ,3 ]
Sanchez-Iglesias, Sofia [1 ]
Cobelo-Gomez, Silvia [1 ]
Prado-Morana, Teresa [1 ,2 ]
Araujo-Vilar, David [1 ,2 ]
机构
[1] Univ Santiago De Compostela, Dept Psychiat Radiol Publ Hlth Nursing & Med, UETeM Mol Pathol Grp, IDIS CIMUS, Santiago De Compostela 15706, Spain
[2] Univ Clin Hosp Santiago De Compostela, Div Endocrinol & Nutr, Santiago De Compostela 15706, Spain
[3] CIBER Fisiopatol Obes & Nutr CIBERobn, Madrid 28029, Spain
关键词
LMNA; Dunnigan disease; type 2 familial partial lipodystrophy; laminopathies; FPLD2; MULTIPLE SYMMETRIC LIPOMATOSIS; ACTIVATED RECEPTOR-GAMMA; LAMIN A/C LMNA; DUNNIGAN-TYPE; ADIPOSE-TISSUE; INSULIN-RESISTANCE; MISSENSE MUTATIONS; R482W MUTATION; NUCLEAR LAMIN; MANDIBULOACRAL DYSPLASIA;
D O I
10.3390/cells12050725
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the LMNA gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to better describe FPLD2. For this purpose, a systematic review through a search on PubMed until December 2022 was conducted and the references of the retrieved articles were also screened. A total of 113 articles were included. FPLD2 is characterised by the loss of fat starting around puberty in women, affecting limbs and trunk, and its accumulation in the face, neck and abdominal viscera. This adipose tissue dysfunction conditions the development of metabolic complications associated with insulin resistance, such as diabetes, dyslipidaemia, fatty liver disease, cardiovascular disease, and reproductive disorders. However, a great degree of phenotypical variability has been described. Therapeutic approaches are directed towards the associated comorbidities, and recent treatment modalities have been explored. A comprehensive comparison between FPLD2 and other FPLD subtypes can also be found in the present review. This review aimed to contribute towards augmenting knowledge of the natural history of FPLD2 by bringing together the main clinical research in this field.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] A case report of 'atypical' familial partial lipodystrophy type 2 (Dunnigan type 2)
    Cronin, T.
    Rasheed, E.
    Mac Aogain, M.
    Savage, S.
    Walsh, E.
    Pazderska, A.
    Crowley, V. E. F.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 105 - 105
  • [32] Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated Familial Partial Lipodystrophy women
    Viola, Luiz F.
    Valerio, Cynthia M.
    Araujo-Neto, Joao M.
    Santos, Fabio F.
    Matsuura, Felipe
    Moreira, Rodrigo O.
    Godoy-Matos, Amelio F.
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01):
  • [33] Waist circumference is independently associated with liver steatosis and fibrosis in LMNA-related and unrelated Familial Partial Lipodystrophy women
    Luiz F. Viola
    Cynthia M. Valerio
    João M. Araujo-Neto
    Fabio F. Santos
    Felipe Matsuura
    Rodrigo O. Moreira
    Amélio F. Godoy-Matos
    Diabetology & Metabolic Syndrome, 15
  • [34] Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2;: MIM 151660)
    Lanktree, M.
    Cao, H.
    Rabkin, S. W.
    Hanna, A.
    Hegele, R. A.
    CLINICAL GENETICS, 2007, 71 (02) : 183 - 186
  • [35] Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2
    Lazarte, Julieta
    Wang, Jian
    McIntyre, Adam D.
    Hegele, Robert A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (05) : 653 - 657
  • [36] Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants
    Sekizkardes, Hilal
    Cochran, Elaine
    Malandrino, Noemi
    Garg, Abhimanyu
    Brown, Rebecca J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08): : 3068 - 3076
  • [37] Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects
    Gambineri, Alessandra
    Zanotti, Laura
    NUCLEUS, 2018, 9 (01) : 392 - 397
  • [38] Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in the LMNA gene
    Schmidt, HHJ
    Genschel, J
    Baier, P
    Schmidt, M
    Ockenga, J
    Tietge, UJF
    Pröpsting, M
    Büttner, C
    Manns, MP
    Lochs, H
    Brabant, G
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (05): : 2289 - 2295
  • [39] Kobberling type of familial partial lipodystrophy - An underrecognized syndrome
    Herbst, KL
    Tannock, LR
    Deeb, SS
    Purnell, JQ
    Brunzell, JD
    Chait, A
    DIABETES CARE, 2003, 26 (06) : 1819 - 1824
  • [40] Clinical Utility Gene Card for: Familial partial lipodystrophy
    Jeru, Isabelle
    Vatier, Camille
    Araujo-Vilar, David
    Vigouroux, Corinne
    Lascols, Olivier
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2017, 25 (02) : 271 - 271